Kusakabe, Y., Chiba, T., Oshima, M., Koide, S., Rizq, O., Aoyama, K., . . . Kato, N. (2021). EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma. Nature Portfolio.
Chicago Style (17th ed.) CitationKusakabe, Yuko, et al. EZH1/2 Inhibition Augments the Anti-tumor Effects of Sorafenib in Hepatocellular Carcinoma. Nature Portfolio, 2021.
MLA (8th ed.) CitationKusakabe, Yuko, et al. EZH1/2 Inhibition Augments the Anti-tumor Effects of Sorafenib in Hepatocellular Carcinoma. Nature Portfolio, 2021.
Warning: These citations may not always be 100% accurate.